Clinical trial
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial…
NCT00263640 · Allergopharma GmbH & Co. KG, Industry · Completed
Key facts
| NCT number | NCT00263640 |
|---|---|
| Title | Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma |
| Official title | A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum.-Adsorbed Allergoid Preparation of House Dust Mite (D. Pteronyssinus) in Patients With Allergic Bronchial Asthma, Rhinitis, Rhinoconjunctivitis |
| Lead sponsor | Allergopharma GmbH & Co. KG, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Respiratory Hypersensitivity |
| Intervention type | Biological, Drug |
| Interventions | Acaroid, Placebo |
| Enrollment | 130 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Aug 1, 2012 |
| First posted | Dec 9, 2005 |
| Last update posted | Jan 15, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: